Switching to monthly berobenatide to keep weight off in adults with overweight or obesity
Tests monthly berobenatide in adults with obesity who already lost weight on semaglutide or tirzepatide.
Plain-language title generated from the registry record
Registry title: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Key facts
- Where
- Birmingham, Butte, Canoga Park, Chesterfield, Cincinnati, Evansville, Flint, Greensboro, Greenville, Jacksonville, Los Angeles, Louisville, Monroe, New Port Richey, Norfolk, Oviedo, Pembroke Pines, Ridgeland, Sacramento, Santa Ana, Walnut Creek, West Hills, and Wilmington, United StatesSee the 24 sites
- Phase
- Phase 3
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesTaking people
- Mercury Street Medical Group, PLLCButte, United StatesTaking people
- San Fernando Valley Health InstituteCanoga Park, United StatesTaking people
- Clinical Research ProfessionalsChesterfield, United StatesTaking people
- Velocity Clinical Research, Mt. AuburnCincinnati, United StatesTaking people
- MediSphere Medical Research Center, LLCEvansville, United StatesTaking people
- Aa Mrc LlcFlint, United StatesTaking people
- Medication Management LLCGreensboro, United StatesTaking people
- Tribe Clinical Research LLCGreenville, United StatesTaking people
- Jacksonville Center for Clinical ResearchJacksonville, United StatesTaking people
- Westside Center for Clinical ResearchJacksonville, United StatesNot yet recruiting
- Velocity Clinical Research, Los AngelesLos Angeles, United StatesTaking people
- Monroe Biomedical ResearchLouisville, United StatesTaking people
- Monroe Biomedical ResearchMonroe, United StatesNot yet recruiting
- Suncoast Clinical ResearchNew Port Richey, United StatesTaking people
- York Clinical Research LLCNorfolk, United StatesNot yet recruiting
- Oviedo Medical ResearchOviedo, United StatesTaking people
- Center for Diabetes, Obesity and Metabolism IncPembroke Pines, United StatesNot yet recruiting
- SKY Integrative Medical Center/SKYCRNGRidgeland, United StatesNot yet recruiting
- Headlands Research- SacramentoSacramento, United StatesNot yet recruiting
- Southern California Clinical ResearchSanta Ana, United StatesTaking people
- Diablo Clinical Research, LLC dba Flourish ResearchWalnut Creek, United StatesTaking people
- Southern California Retina SpecialistsWest Hills, United StatesTaking people
- Accellacare - WilmingtonWilmington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07845500
- Record updated
- 5 November 2026
- Original description
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.Read full original descriptionShow less
A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.
Participants will be in the study for about 11 months.
Inclusion: Aged ≥18 years; Currently taking semaglutide or tirzepatide for obesity management.
Exclusion: Diagnosis of any form of diabetes; History of acute or chronic pancreatitis; Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).